How a thourough feasibility helps to launch clinical trials with confidence rather than hope.
Clinical trial feasibility determines whether your drug or device study can realistically succeed within planned timelines and budgets before significant investment flows into execution. Smart feasibility assessment examines every element that could impact your study’s success while poor upfront evaluation creates extended timelines, recruitment failures, and budget overruns that derail even the most promising treatments.
In our feasibility assessment, we look at:
- patient availability at potential research sites,
- investigator expertise,
- protocol complexity,
- regulatory pathways,
- operational logistics.
We help you prevent:
- sites that promise patient populations they cannot deliver,
- protocols that assume recruitment rates that exist only on paper,
- regulatory timelines that stretch beyond initial projections.
Get in touch with us
What clinical trial feasibility means
Clinical trial feasibility assessment determines whether you can execute your protocol within planned timelines and budgets while meeting recruitment targets. This upfront evaluation charts the path between protocol design and successful study completion. We analyze protocol requirements against real-world performance data to identify potential roadblocks that could derail your journey.
Proper feasibility assessment moves far beyond theoretical patient numbers found in databases. Trial data available to CROs might reveal actual recruitment rates of 0.23 patients per site per month, while the sponsor was planning with a rate of 1.2 patients. This five-fold gap between projections and reality creates timeline extensions that sponsors rarely anticipate during protocol design.
The impact of feasibility on trial success
The difference between successful studies and those requiring rescue plans often comes down to honest feasibility planning from day one. Poor feasibility planning forces sponsors down expensive paths: extended timelines, mid-study site additions, or premature enrollment termination. A Phase I/II trial projected for 24 months recruitment might realistically require 30 months from first patient in to last patient out when actual site performance data guides projections.
Smart feasibility work prevents the crisis management that derails promising treatments before they reach patients who need them.
Critical Factors That Shape Trial Feasibility
Trial feasibility success depends on multiple interconnected elements working together rather than individual components operating in isolation and determine whether your protocol transitions from design to successful execution.
Site identification and country selection
Country selection reflects multiple factors working together:
- Manufacturing site proximity for logistics efficiency
- Patient availability
- CRO network relationships and site performance history
- Competitive trial environment and regulatory pathways
Countries with proven feasibility combine feasible logistics, investigator experience, and established research networks.
Site capabilities and investigator expertise
Site selection criteria require specialized knowledge that goes far beyond geographic convenience.
- Investigator expertise in your therapeutic area directly impacts screening efficiency and protocol adherence.
- Sites lacking genuine conviction or do not see enough patients or lack adequate resources consistently underperform during recruitment, regardless of their optimistically stated patient population size. Site motivation plays a role that sponsors often underestimate. Experience shows sites lacking conviction about your investigational product deliver weaker recruitment results, regardless of their optimistically stated patient population.
Protocol design and patient recruitment realities
Recruitment projections frequently ignore actual performance data from similar studies. For example, databases reveal recruitment rates of 0.1 to 0.2 patients per site per month in specialized indications, yet protocols routinely assume one patient per site monthly. This extends timelines significantly beyond initial projections. Therefore, protocol analysis starts with inclusion and exclusion criteria that directly shape recruitment success. Vague requirements create screening failures that sponsors never see coming.
- Inclusion criteria precision delivers better results than overly broad requirements. Vague criteria like “history of chronic expectoration” generate screening failures that slow enrollment. Defining specific timeframes, such as “within two months before screening”, helps sites identify qualified patients more efficiently.
- Overly broad exclusion criteria create patient dropouts that compromise retention and data integrity. They create poor participant retention and patient dropouts that compromise data integrity.
- Real-World patient journeys should be compared to the protocol, supported by indication experts or even patients.
Supply chain and regulatory coordination
IMP development timelines and manufacturing capacity create constraints that affect study launch dates. Manufacturing site location influences country selection, as proximity reduces logistics complexity and associated costs. Regulatory submissions to authorities and ethics committees follow different timelines across regions, with potential system deficiencies adding unpredictable delays to activation schedules.
Start-up timeline management
Five-six month start-up periods for drug studies become achievable when regulatory submissions, site contracts, and vendor agreements proceed simultaneously rather than sequentially. Did you know that Start-up coordination represents one of the most challenging aspects of clinical trial execution? Unexpected delays in IMP availability, sponsor document approvals, or regulatory responses extend activation timelines beyond initial projections, requiring contingency planning from the beginning.
Steps to Perform Smart Clinical Trial Feasibility Assessment
Smart feasibility assessment follows a systematic approach that turns protocol assumptions into reality-based projections.
We walk you through each essential step to ensure your study launches with accurate enrollment timelines and committed investigator networks:
Timeline development with realistic buffers
Five to six month start-up periods only work when regulatory submissions, site contracts, and vendor agreements proceed simultaneously. Build timeline buffers for potential delays with IMP development, regulatory responses, or system implementation issues beyond direct control.
Supporting sponsors through expert clinical trial feasibility planning
Feasibility assessment excellence demands partnering with CROs that unite therapeutic expertise with real-world execution capabilities. Especially early phase trials demand specialized knowledge that standard CROs often lack.
We bring more than two decades of experience across 650 studies to feasibility planning that works for biotech /drug development companies and medical device sponsors.
FGK’s track record includes hundreds of early phase projects, with specific expertise, i.e. in first-in-human studies, rare diseases, and orphan drugs . These complex protocols require safety monitoring capabilities and investigator expertise that create unique feasibility challenges.
The combination of therapeutic knowledge and biostatistical support for adaptive designs creates the foundation for realistic feasibility assessment.
Our medical monitors and safety physicians provide the clinical oversight needed for early phase trial success.
Proven site networks and recruitment strategies
European networks built over decades provide the relationships that make feasibility assessments accurate. Our presence spans all over Europe, with subsidiaries that enable direct site evaluation rather than theoretical projections.
- We contact sites across suitable countries to identify the most promising locations while maintaining backup options. This approach reduces risk when recruitment proves slower than anticipated or regulatory delays emerge unexpectedly.
- We evaluate investigator track records with similar drug or device protocols and assess their commitment to your product before activation begins.
- We identify investigators who demonstrate genuine commitment to your study objectives. Their enthusiasm directly influences enrollment rates throughout study duration.
The difference for successful versus static study site management lies in relationships that go beyond contracts. Our Clinical Research Associates maintain close contact with investigators, offering administrative support and site training that builds genuine commitment.
Why chose FGK as your CRO for a high-end clinical trial feasibility and seamless study start-up
FGK’s staff turnover has been or around 3% for many years, ensuring project continuity when feasibility transitions to execution. Senior management involvement in all research projects creates direct accountability for timeline and budget projections. Flat organizational structure enables quick decision-making when feasibility assessment reveals potential obstacles.
Our biotech CRO services and as well our services for medical device sponsors include optional eSolutions for eCRF, eTMF, and CTMS that provide sponsors the operational foundation needed for study start-up while maintaining the flexibility that changing feasibility insights might demand.
Partnership with experienced clinical research specialists replaces guesswork with data-driven projections. We set realistic enrollment targets that emerge from actual site performance rather than wishful thinking. Our goal is to find committed investigators surface through proper evaluation rather than geographical convenience.
Conclusion
The difference between trials that meet milestones and those requiring sponsors costly extensions often lies in the quality of upfront planning and support thereof. When feasibility assessment uncovers potential obstacles before they derail your study, smooth execution becomes achievable rather than accidental.
Your clinical research and development success deserves the foundation that only expert feasibility planning provides. We bring the expertise needed to launch studies with confidence rather than hope.